Siqing Fu

Siqing Fu is a Senior Professor at The University of Texas MD Anderson Cancer Center, specializing in oncology, cancer pharmacology, and early-phase clinical trials. His research focuses on developing novel cancer immunotherapies, targeted inhibitors, and antibody–drug conjugates for advanced solid tumors, including KRAS G12D inhibitors and B7H3-targeting agents. His recent publications include a phase 1/1b trial of a B7H3-targeting antibody–drug conjugate in Nature Medicine and updated results of TSN1611 in the Journal of Clinical Oncology. He also investigates telemedicine’s role in expanding access to early-phase oncology trials, drawing on data from over 14,000 patients. His work encompasses platinum-resistant ovarian cancer, renal cell carcinoma, and non-small cell lung cancer, with a strong emphasis on translational research and global clinical trial equity.